Antonio Rodríguez-Fernández

Antonio Rodríguez-Fernández

Auto-generated profile, based on publicly available information

Antonio Rodríguez-Fernández

Nuclear Medicine Department, Hospital Virgen de las Nieves, Granada, Spain

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2010 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
PPPablo Palma
Pablo Palma
RCRaquel Conde-Muíño
Raquel Conde-Muíño
ARAntonio Rodríguez-Fernández
Antonio Rodríguez-Fernández
ISInmaculada Segura-Jiménez
Inmaculada Segura-Jiménez
RSRocío Sánchez-Sánchez
Rocío Sánchez-Sánchez
JLJose Manuel Llamas-Elvira
Jose Manuel Llamas-Elvira
We aim to investigate the possibility of using 18F-positron emission tomography/computer tomography (PET-CT) to predict the histopathologic response in locally advanced rectal cancer (LARC) treated with preoperative chemoradiation (CRT).

13 October 2014 in BJU International
Verified
Journal Article
Open access
PDF file
SRSonia Rodado‐Marina
Sonia Rodado‐Marina
MCMónica Coronado‐Poggio
Mónica Coronado‐Poggio
AGAna María García‐Vicente
Ana María García‐Vicente
JGJose Ramón García‐Garzón
Jose Ramón García‐Garzón
JAJuan Carlos Alonso‐Farto
Juan Carlos Alonso‐Farto
ARAntonio Rodríguez‐Fernández
Antonio Rodríguez‐Fernández
Objective: To evaluate 18 F ‐fluorocholine positron‐emission tomography ( PET )/computed tomography ( CT ) in restaging patients with a history of prostate adenocarcinoma who have biochemical relapse after early radical treatment, and to correlate the technique's disease detection rate with a set of variables and clinical and pathological parameters. Patients and Methods: This was a retrospective multicentre study that included 374 patients referred for choline‐ PET / CT who had biochemical relapse. In all, 233 patients who met the following inclusion criteria were analysed: diagnosis of prostate cancer; early radical treatment; biochemical relapse; main clinical and pathological variables; and clinical, pathological and imaging data needed to validate the results. Criteria used to validate the PET / CT : findings from other imaging techniques, clinical follow‐up, treatment response and histological analysis. Different statistical tests were used depending on the distribution of the data to correlate the results of the choline‐ PET / CT with qualitative [ T stage, N stage, early radical prostatectomy ( RP ) vs other treatments, hormone therapy concomitant to choline‐ PET / CT ] and quantitative [age, G leason score, prostate‐specific antigen ( PSA ) levels at diagnosis, PSA nadir, PSA level on the day of the choline‐ PET / CT ( T rigger PSA ) and PSA doubling time ( PSADT )] variables. We analysed whether there were independent predictive factors associated with positive PET / CT results. Results: Choline‐ PET / CT was positive in 111 of 233 patients (detection rate 47.6%) and negative in 122 (52.4%). Disease locations: prostate or prostate bed in 26 patients (23.4%); regional and/or distant lymph nodes in 52 (46.8%); and metastatic bone disease in 33 (29.7%). Positive findings were validated by: results from other imaging techniques in 35 patients (15.0%); at least 6 months of clinical follow‐up in 136 (58.4%); treatment response in 24 (10.3%); histological analysis of lesions in 17 (7.3%); and follow‐up plus imaging results in 21 (9.0%). The statistical analysis of qualitative variables, corresponding to patients' clinical characteristics, and the positive/negative final PET / CT results revealed that only whether or not early treatment with RP was done was statistically significant ( P < 0.001), with the number of positive results higher in patients who did not undergo a RP . Among the quantitative variables, G leason score, T rigger PSA and PSADT clearly differentiated the two patient groups (positive and negative choline‐ PET / CT : P = 0.010, P = 0.001 and P = 0.025, respectively). A G leason score of <5 or ≥8 clearly differentiated positive from negative PET . Trigger PSA : mean of 8 ng/mL for positive PET / CT vs 2.8 ng/mL for negative PET / CT ; PSADT : mean of 8 months for positive vs 12.6 months for negative. The optimal threshold values were: 3 ng/mL for Trigger PSA level and 6 months for PSADT ( Y ouden index/receiver operating characteristic curve). Analysing these two variables together showed that PSADT was more conclusive in patients with lower T rigger PSA levels. Analysing variables by location showed that only PSADT was able to differentiate between those with disease confined to the prostate compared with the other two locations (lymph nodes and bone), with shorter PSADT in these two, which was statistically significant ( P < 0.002). In the patient group with a PSA level of <1.5 ng/mL, 30.8% had the disease, 7% of whom had metastatic bone disease. In the multivariate logistic regression, the risks factors that were clearly independent for those with positive PET / CT were: PSA level of >3 ng/mL, no early RP , and G leason score of ≥8. Conclusion: Our results support the usefulness of 18 F ‐fluorocholine PET / CT in biochemical relapse of prostate cancer after radical treatment, with an overall disease detection rate close to 50%, and it can be recommended as first‐line treatment. As mentioned above, besides T rigger PSA levels, there are other clinical and pathological variables that need to be considered so as to screen patients properly and thus minimise the number of nodular lesions and increase the diagnostic accuracy of the examination.

25 September 2023 in Clinical and Translational Oncology
Verified
Journal Article
Open access
PDF file
EGEncarna González-Flores
Encarna González-Flores
NZNatalia Zambudio
Natalia Zambudio
PMPedro Pardo Moreno
Pedro Pardo Moreno
BAB. Gonzalez Astorga
B. Gonzalez Astorga
JRJorge Roldán de la Rúa
Jorge Roldán de la Rúa
ARAntonio Rodríguez-Fernández
Antonio Rodríguez-Fernández
Purpose: Strategies for the treatment of liver metastases from colon cancer (lmCRC) are constantly evolving. Radioembolization with yttrium 90 (Y-90 TARE) has made significant advancements in treating liver tumors and is now considered a potential option allowing for future resection. This study reviewed the scientific evidence and developed recommendations for using Y-90 TARE as a treatment strategy for patients with unresectable lmCRC. Methods: A multidisciplinary scientific committee, consisting of experts in medical oncology, hepatobiliary surgery, radiology, and nuclear medicine, all with extensive experience in treating patients with ImCRC with Y-90 TARE, led this project. The committee established the criteria for conducting a comprehensive literature review on Y-90 TARE in the treatment of lmCRC. The data extraction process involved addressing initial preliminary inquiries, which were consolidated into a final set of questions. Results: This review offers recommendations for treating patients with lmCRC using Y-90 TARE, addressing four areas covering ten common questions: 1) General issues (multidisciplinary tumor committee, indications for treatment, contraindications); 2) Previous process (predictive biomarkers for patient selection, preintervention tests, published evidence); 3) Procedure (standard procedure); and 4) Post-intervention follow-up (potential toxicity and its management, parameters for evaluation, quality of life). Conclusions: Based on the insights of the multidisciplinary committee, this document offers a comprehensive overview of the technical aspects involved in the management of Y-90 TARE. It synthesizes recommendations for applying Y-90 TARE across various phases of the treatment process.

2 July 2022 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
JAJ. C. Alonso
J. C. Alonso
ICI. Casans
I. Casans
FGF. M. González
F. M. González
DFD. Fuster
D. Fuster
ARA. Rodríguez
A. Rodríguez
NCNataly Espinoza Cámac
Nataly Espinoza Cámac
Background: Transarterial radioembolization (TARE) with yttrium-90 microspheres is a clinically effective therapy for hepatocellular carcinoma (HCC) treatment. This study aimed to perform a systematic review of the available economic evaluations of TARE for the treatment of HCC. Methods: The Preferred Reported Items for Systematic reviews and Meta-Analyses guidelines was followed by applying a search strategy across six databases. All studies identified as economic evaluations with TARE for HCC treatment in English or Spanish language were considered. Costs were adjusted using the 2020 US dollars based on purchasing-power-parity ($US PPP). Results: Among 423 records screened, 20 studies (6 cost-analyses, 3 budget-impact-analyses, 2 cost-effectiveness-analyses, 8 cost-utility-analyses, and 1 cost-minimization analysis) met the pre-defined criteria for inclusion. Thirteen studies were published from the European perspective, six from the United States, and one from the Canadian perspectives. The assessed populations included early- (n = 4), and intermediate-advanced-stages patients (n = 15). Included studies were evaluated from a payer perspective (n = 20) and included both payer and social perspective (n = 2). TARE was compared with transarterial chemoembolization (TACE) in nine studies or sorafenib (n = 11). The life-years gained (LYG) differed by comparator: TARE versus TACE (range: 1.3 to 3.1), and TARE versus sorafenib (range: 1.1 to 2.53). Of the 20 studies, TARE was associated with lower treatment costs in ten studies. The cost of TARE treatment varied widely according to Barcelona Clinic Liver Cancer (BCLC) staging system and ranged from 1311 $US PPP/month (BCLC-A) to 71,890 $US PPP/5-years time horizon (BCLC-C). The incremental cost-utility ratio for TARE versus TACE resulted in a 17,397 $US PPP/Quality-adjusted-Life-Years (QALY), and for TARE versus sorafenib ranged from dominant (more effectiveness and lower cost) to 3363 $US PPP/QALY. Conclusions: Economic evaluations of TARE for HCC treatment are heterogeneous. Overall, TARE is a cost-effective short- and long-term therapy for the treatment of intermediate-advanced HCC.

27 December 2021 in Diagnostics
Verified
Journal Article
Open access
PDF file
TRTeodoro Rudolphi-Solero
Teodoro Rudolphi-Solero
ETEva María Triviño-Ibáñez
Eva María Triviño-Ibáñez
AMAntonio Medina-Benítez
Antonio Medina-Benítez
JFJavier Fernández-Fernández
Javier Fernández-Fernández
DRDaniel José Rivas-Navas
Daniel José Rivas-Navas
ARAntonio Rodríguez-Fernández
Antonio Rodríguez-Fernández
Fibrolamellar hepatocellular carcinoma is a primary hepatic tumor that usually appears in young adults. Radical surgery is considered curative for this kind of tumor, so early diagnosis becomes essential for the prognosis of the patients. The main characteristic of this entity is the central scar, which is the center of differential diagnosis. We report the case of a 30-year-old man who was diagnosed with fibrolamellar hepatocellular carcinoma by ultrasonography. Contrast-enhanced CT confirmed this diagnosis, and the patient underwent a [18F] fluorocholine PET/CT. Hypermetabolism and the morphology in the nuclear medicine exploration suggest neoplastic nature of the lesion. Radical surgery was performed, and histopathologic analysis was performed, which resulted in focal nodular hyperplasia. Hepatic masses with central scar could have a difficult differential diagnosis, and focal nodular hyperplasia could mimic fibrolamellar hepatocellular carcinoma imaging patterns. These morphofunctional characteristics have not been described in [18F] Fluorocholine PET/CT, so there is a need to find out the potential role PET/CT in the differential diagnosis of hepatic mass with central scar.

24 May 2023 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
JAJc Alonso
Jc Alonso
ICI Casans
I Casans
FGFm González
Fm González
DFD Fuster
D Fuster
ARA Rodríguez
A Rodríguez
NEN Espinoza
N Espinoza
Background: Transarterial radioembolization with yttrium-90 (Y-90 TARE) microspheres therapy has demonstrated positive clinical benefits for the treatment of liver metastases from colorectal cancer (lmCRC). This study aims to conduct a systematic review of the available economic evaluations of Y-90 TARE for lmCRC. Methods: English and Spanish publications were identified from PubMed, Embase, Cochrane, MEDES health technology assessment agencies, and scientific congress databases published up to May 2021. The inclusion criteria considered only economic evaluations; thus, other types of studies were excluded. Purchasing-power-parity exchange rates for the year 2020 ($US PPP) were applied for cost harmonisation. Results: From 423 records screened, seven economic evaluations (2 cost-analyses [CA] and 5 cost-utility-analyses [CUA]) were included (6 European and 1 USA). All included studies (n = 7) were evaluated from a payer and the social perspective (n = 1). Included studies evaluated patients with unresectable liver-predominant metastases of CRC, refractory to chemotherapy (n = 6), or chemotherapy-naïve (n = 1). Y-90 TARE was compared to best supportive care (BSC) (n = 4), an association of folinic acid, fluorouracil and oxaliplatin (FOLFOX) (n = 1), and hepatic artery infusion (HAI) (n = 2). Y-90 TARE increased life-years gained (LYG) versus BSC (1.12 and 1.35 LYG) and versus HAI (0.37 LYG). Y-90 TARE increased the quality-adjusted-life-year (QALY) versus BSC (0.81 and 0.83 QALY) and versus HAI (0.35 QALY). When considering a lifetime horizon, Y-90 TARE reported incremental cost compared to BSC (range 19,225 to 25,320 $US PPP) and versus HAI (14,307 $US PPP). Y-90 TARE reported incremental cost-utility ratios (ICURs) between 23,875 $US PPP/QALY to 31,185 $US PPP/QALY. The probability of Y-90 TARE being cost-effective at £ 30,000/QALY threshold was between 56% and 57%. Conclusions: Our review highlights that Y-90 TARE could be a cost-effective therapy either as a monotherapy or when combined with systemic therapy for treating ImCRC. However, despite the current clinical evidence on Y-90 TARE in the treatment of ImCRC, the global economic evaluation reported for Y-90 TARE in ImCRC is limited (n = 7), therefore, we recommend future economic evaluations on Y-90 TARE versus alternative options in treating ImCRC from the societal perspective.